Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: A case report

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kim, Dae Won ^a   Barcena, Edelyn ^a   Mehta, Urvi N ^a   Rohlfs, Michelle L ^a   Kumar, Ashok J ^a   Penas Prado, Marta ^a   Kim, Kevin B ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

BRAF inhibitors; Leptomeningeal disease; Metastatic melanoma

Indexed keywords

ABEOTAXANE; ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; IPILIMUMAB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; BRAIN RADIATION; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; ENZYME INHIBITION; FATIGUE; HUMAN; LUNG LOBECTOMY; LUNG METASTASIS; LYMPH NODE DISSECTION; MALE; MELANOMA; MENINGEAL METASTASIS; METASTATIC MELANOMA; OUTCOME ASSESSMENT; PERITONEUM METASTASIS; PHOTOSENSITIVITY; REPEATED DRUG DOSE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL TIME; ANTAGONISTS AND INHIBITORS; GENETICS; MENINGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84929455236     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1391-x     Document Type: Article

References (31)

1. Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16(8):1175-88.
2. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660-8.
3. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008;10(6):1010-8.
4. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687-96.
5. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53(7):626-32.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
7. Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Helias-Rodzewicz Z, et al. Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012;19(13):4314-21.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
9. Chapman PB, Hauschild A, Robert C, Larkin J, Haanen J, Ribas A. Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAF V600E-mutated melanoma. In: Ammerical Society of Clinical Oncology (ASCO) annual meeting. vol. 30. Chicago, Illinois; 2012: 8502.
10. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
11. Hauschild A, Grob JJ, Jouary T, Gutzmer R, Millward M, Rutkowski P et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). In: Americal Society of Clinical Oncology (ASCO) annual meeting vol. 31. Chicago, Illinois; 2013: 9013.
12. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-95.
13. Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol. 2012;259(9):1976-8.
14. Hottinger AF, Favet L, Pache JC, Martin JB, Dietrich PY. Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis. Case Rep Oncol. 2011;4(1):211-5.
15. Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, et al. Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo. 2012;26(6):1079-86.
16. Schaefer N, Rasch K, Moehlenbruch M, Urbach H, Stuplich M, Blasius E, et al. Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine. Acta Oncol. 2011;50(8):1260-2.
17. Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkamper C, et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol. 2013;31(11):e173-4.
18. Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res. 2013;23(2):175-8.
19. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-9.
20. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-88.
21. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32(33):3697-704.
22. d'Avella D, Cicciarello R, Albiero F, Mesiti M, Gagliardi ME, Russi E, et al. Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery. 1992;30(1):30-4.
23. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40(3):648-77.
24. Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990;19(6):1507-10.
25. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25(16):2306-12.
26. Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer. 2001;93(1):62-6.
27. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4 Suppl 4:S265-88.
28. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest. 2005;23(2):145-54.
29. Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA et al. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma. In: Americal Society of Clinical Oncology (ASCO) Annual Meeting. vol. 29; 2011: 8519.
30. Amaravadi RK, Kim KB, Flaherty KT, Chapman PB, Puzanov I, Sosman JA et al: Prolonged responses to vemurafenib in patients with BRAF V600E mutant melanoma with low tumor burden at baseline. In: The Society for Melanoma Research 2011 international Congress: 2011; Tempa, Florida; 2011.
31. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74(18):1449-54.